FEDERAL COURT OF AUSTRALIA
Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2012] FCA 1510
Citation: Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd [2012] FCA 1510 Parties: BAYER PHARMA AKTIENGESELLSCHAFT and BAYER AUSTRALIA LIMITED (ACN 000 138 714) v GENERIC HEALTH PTY LTD (ACN 110 617 859) and LUPIN AUSTRALIA PTY LIMITED (ACN 112 038 105) File number: NSD 236 of 2012 Judge: YATES J Date of judgment: 14 December 2012 Catchwords: PATENTS – patent amendment application – whether discretion under s 105 of the Patents Act 1990 (Cth) should be exercised in favour of making the amendments sought – consideration of whether unreasonable delay, covetous claiming or unfair advantage present Legislation: Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Patents Act 1990 (Cth) ss 40, 102, 105, 122, 123
Federal Court Rules 2011 (Cth) r 34.41Cases cited: Apotex Pty Ltd v Les Laboratoires Servier (No 2) (2009) 83 IPR 42
Apotex Pty Ltd v Les Laboratoires Servier (No 3) [2009] FCA 1069
Autoliv Development AB’s Patent [1988] RPC 425
Bristol-Myers Squibb Co v Apotex Pty Ltd (2010) 87 IPR 516
CSL Limited v Novo Nordisk Pharmaceuticals Pty Ltd (No 3) [2010] FCA 1279
CSL Ltd v Novo Nordisk Pharmaceuticals Pty Ltd (No 2) (2010) 190 FCR 522
Gambro Pty Ltd v Fresenius Medical Care South East Asia Pty Ltd [2000] FCA 407
Gedeon Richter plc v Bayer Schering Pharma AG [2011] EWHC 583 (Pat)
ICI Chemicals & Polymers Ltd v Lubrizol Corp (1999) AIPC 91-521
Imperial Chemical Industries Ltd (Whyte’s) Patent [1978] RPC 11
Les Laboratoires Servier v Apotex Pty Ltd (2010) 273 ALR 630
Lockwood Security Products Pty Limited v Doric Products Pty Limited (2004) 217 CLR 274
Novartis AG v Bausch & Lomb (Australia) Pty Ltd (2004) 62 IPR 71
Rescare Ltd v Anaesthetic Supplies Pty Ltd (unreported, Gummow J, 4 March 1993)
Smith Kline & French Laboratories Limited v Evans Medical Limited [1989] 1 FSR 561
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Limited (No 2) (1997) 74 FCR 306
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd (No 3) (1997) AIPC 91-366
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd (unreported, Sundberg J, 12 November 1997)Aldous W, Young D, Watson A, Thorley S, Terrell on the Law of Patents (13th ed, Sweet & Maxwell, 1982)
Thorley S, Miller R, Burkill G, Birss C, Terrell on the Law of Patents (15th ed, Sweet & Maxwell, 2000)Dates of hearing: 18, 19, 20 June 2012 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 233 Counsel for the Applicant (Bayer Pharma Aktiengesellschaft): Mr D Shavin QC and Ms HMJ Rofe Solicitor for the Applicant (Bayer Pharma Aktiengesellschaft): Davies Collison Cave Law Pty Ltd Counsel for the Respondents: Ms AH Bowne SC and Ms MV McCarthy Solicitor for the Respondents: Middletons Counsel for the Opponent (Eremad Pty Limited): Mr DK Catterns QC Solicitor for the Opponent (Eremad Pty Limited): Ashurst Australia
IN THE FEDERAL COURT OF…
Keep reading for free
Create a free CaseChat account to read Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2012] FCA 1510
- Decision Date
CaseChat Overview and Summary
The key legal issue was whether Bayer Pharma's application for patent amendments should be allowed, considering the principles of unreasonable delay, covetous claiming, and unfair advantage. The respondents argued that the application was untimely and that granting the amendments would confer an unfair advantage. Bayer Pharma, on the other hand, contended that the amendments were necessary to correct a drafting error and that there was no unreasonable delay.
The Court found that Bayer Pharma had not acted unreasonably in delaying the application for amendments. The Court concluded that the amendments were necessary to correct a drafting error and did not constitute covetous claiming or provide an unfair advantage to Bayer Pharma. The Court also noted that the infringement of the patent by the respondents was ongoing, and the amendments would not change the nature of the infringement claims. Therefore, the discretion under Section 105 of the Act should be exercised in favour of Bayer Pharma.
The Court ordered the patent to be amended as requested by Bayer Pharma, extended the time for appeal against the decision, and stayed the orders pending the publication of the Court's reasons.
Orders
Orders of the court
1. Pursuant to s 105(1) of the Patents Act 1990 (Cth) (the Act), Australian Patent No. 780330 entitled “Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive” be amended in the manner set out in the annexure to the interlocutory application dated 13 April 2012 (the interlocutory application).
2. The time for filing any application for leave to appeal from the orders made by the Court today pursuant to s 105(1) of the Act be extended until the date which is 14 days after the publication of the Court’s reasons for judgment on the interlocutory application.
3. The orders made by the Court today pursuant to s 105(1) of the Act be stayed pending the date which is 14 days after the publication of the Court’s reasons for judgment on the interlocutory application.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.